Now that NPS Pharmaceuticals Inc. has regained worldwide rights to two Orphan drugs at a discount, the biotech must focus on building its global footprint.

Last week, Takeda Pharmaceutical Co. Ltd. returned ex-North American rights to NPS for Gattex/Revestive teduglutide and Natpara/Preotact recombinant human parathyroid hormone 1-84 (PTH). Takeda, which gained the drugs as part of its 2011 acquisition of Nycomed, will receive 6.1 million NPS shares up front. The shares are valued at $54.9 million based on NPS's closing price of $9.04 on March 18, the day before the deal was announced.